Artemether+Lumefantrine Tablet 20+120mg, 18′s/Box

• Powder: No
• Customized: Customized
• Certification: GMP, Copp
• Suitable for: Adult
• State: Solid
• Purity: >99%
• Model NO.: ANTI-08-02
• Transport Package: Level 3
• Specification: 20+120MG, 18′S/BOX
• Trademark: Serumpharm
• Origin: China
• HS Code: 2901231000

Product Description

ARTEMETHER+LUMEFANTRINE TABLET 20+120MG, 18'S/BOX

Specification: 20+120MG,18'S/BOX
Trademark: Serumpharma
Support OEM/ODM: Yes
Mini. Order: 50000 Boxes
Delivery Time: 30~60 Days
Trade Term: FOB,CIF
Payment Term: T/T,L/C
Standard Available: CP,BP
Documents: GMP,COPP,CTD

Description:

ARTEMETHER+LUMEFANTRINE TABLET 20+120MG

Indicatios:
Compound Artemether Tablets is indicated for the treatment of acute uncomplicated Plasmodium falciparum malaria in adults, children and infants of 5 kg and above.
Dosage and administration:
Compound Artemether Tablets should be taken with food.
Tablets may be crushed and mixed with water immediately prior to administration to patients, including children.
Compound Artemether Tablets should be administered over 3 days for a total of 6 doses: an initial dose, second dose after 8 hours, and then twice-daily (morning and evening) for the following 2 days.
The adult dosage for patients with bodyweight of 35 kg and above is 4 tablets per dose for a total of 6 doses. The number of tablets per dose for children is determined by bodyweight.
Contraindications:
Known hypersensitivity to artemether, lumefantrine, or to any of the excipients.
Coadministration of strong inducers of CYP3A4 such as rifampin, carbamazepine,
phenytoin, and Perforate St John's-wort with Compound Artemether Tablets.
Precautions:
l Compound Artemether Tablets is not recommended during the first trimester of pregnancy in situations where other suitable and effective antimalarials are available.
l Compound Artemether Tablets has not been evaluated for the treatment of severe malaria, including cases of cerebral malaria or other severe manifestations such as pulmonary oedema or renal failure.
l Due to limited data on safety and efficacy, Compound Artemether Tablets should not be given concurrently with any other antimalarial agent unless there is no other treatment option.
l If a patient deteriorates whilst taking Compound Artemether Tablets, alternative treatment for malaria should be started without delay.  In such cases, monitoring of the ECG is recommended and steps should be taken to correct any electrolyte disturbances.
l Caution is recommended when combining Compound Artemether Tablets with drugs exhibiting variable patterns of inhibition, moderate induction or competition for CYP3A4 as the therapeutic effects of some drugs could be altered.  
l Caution is recommended when combining Compound Artemether Tablets with hormonal contraceptives.  Compound Artemether Tablets may reduce the effectiveness of hormonal contraceptives.  
l Patients who remain averse to food during treatment should be closely monitored as the risk of recrudescence may be greater.
l Renal impairment
l Hepatic impairment
l New infections
Drug interactions:
CYP3A4 Inducers: Potential for loss of antimalarial efficacy.
CYP3A4 Inhibitors: Use cautiously due to potential for QT prolongation.
Antiretrovirals: Use cautiously due to potential for QT prolongation, loss of antiviral efficacy, or loss of antimalarial efficacy of Compound Artemether Tablets.
Mefloquine: If used immediately before treatment, monitor for decreased efficacy of Compound Artemether Tablets and encourage food consumption.
Hormonal Contraceptives: Effectiveness may be reduced; use an additional method of birth control.
CYP2D6 Substrates: Monitor for adverse reactions and potential QT prolongation.
Storage:
Do not store above 30°C.


 

Jiangxi Serum Pharma Industries Co.,Ltd. is a professional medical and pharmaceutical products supplier in China. We have been focused on exporting Biological products,Vaccines,Western medicines, APIs, Intermediates and medical products over 10 years, accumulating a wealth of experience. Our products have been exported to more than 30 countries, mainly in Asia, Africa, South America, Middle East and Europe, such as Philippines, Bangladesh,Laos,Cambodia, Kyrghyzstan, Cameroon, Guinea, Nigeria, Liberia, Mali, Yemen, Turkey, Chile, Australia and so on.Our finished products have won great popularity with reliable quality and competitive price,we have numerous end-users and good market reputation. 

We have developed advanced into the leading enterprise in pharmaceutical overseas exporting industry after years of efforts.Our products, including API and finished formulation, have been accredited with various certificates, such as Chinese GMP certificate, ISO9001 quality certificate.

The company has established close cooperation relations with domestic manufacturers of biological products, vaccines, raw material medicines and auxiliary materials, and has shared resources and complementary advantages. we are committed to the development and penetration of the international market and provide customers with quality assurance. We provide various pharmaceutical APIs and finished products with top quality at reasonable price and better after-sales service.

Our company has established a perfect quality assurance system in strict accordance with China's GMP requirements. The entire process from raw material procurement to finished product shipment is controlled by the quality assurance department.All raw materials are provided by selected reliable suppliers and carefully inspected by the Quality Assurance Department before use.

Excellence, Professionalism, and integrity are our cultures. We will offer good quality products with competitive prices and fast delivery for our customers. We are looking forward to setting up long-term cooperation relationship with you.